Using SAS to Assess Dose Proportionality in Dose Escalation Studies
نویسنده
چکیده
Dose escalation studies provide a good opportunity to assess the linearity of PK parameters. This paper describes hypothesis testing and confidence interval (C.I.) methods for assessing dose proportionality based on linear regression and weighted least squares (WLS) linear regression. SAS® code is presented using an example study and AUCinf data.
منابع مشابه
182-31: Empirical Power Estimation for Phase I Dose-Proportionality Studies Based on Power-Law Model Using Confidence Interval Criteria
A Phase I dose-proportionality study is an essential tool to understand drug pharmacokinetic dose-response relationship in early clinical development. There are a number of different approaches to the assessment of dose proportionality. The confidence interval (CI) criteria approach, a staitistically sound and clinically relevant approach, has been proposed to detect dose-proportionality (Smith...
متن کاملExploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.
This article reviews currently used approaches for establishing dose proportionality in Phase I dose escalation studies. A review of relevant literature between 2002 and 2006 found that the power model was the preferred choice for assessing dose proportionality in about one-third of the articles. This article promotes the use of the power model and a conceptually appealing extension, i.e. a cri...
متن کاملA Dose Escalation Method for Dual-Agent in Phase 1 Cancer Clinical Trial using the SAS MCMC Procedure
Continual reassessment method (CRM) is a model-based dose escalation method commonly used to design a phase 1 trial in oncology when evaluating one agent. The main characteristics include the definition of a working model for dose levels, an acceptable level of toxicity (target) and a model defining the dose-toxicity relationship (for example, power or logistic function). This relationship is u...
متن کاملA Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
PURPOSE To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib, in patients with advanced solid malignancies. EXPERIMENTAL DESIGN This phase I dose-escalation study included an expansion phase at the maximum tolerated dose (MTD). Patients received refametinib/sorafenib twice daily for 28 days, from a dose of refametinib 5 mg pl...
متن کاملEscalation strategies for combination therapy Phase I trials
Phase I clinical trials aim to identify a maximum tolerated dose (MTD), the highest possible dose that does not cause an unacceptable amount of toxicity in the patients. In trials of combination therapies, however, many different dose combinations may have a similar probability of causing a dose-limiting toxicity, and hence, a number of MTDs may exist. Furthermore, escalation strategies in comb...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005